Varex Imaging CorpVREX
Price$18.45Intrinsic value$17.256% below price

Qualitative Analysis

Business overview

Business Overview

Varex Imaging Corporation (NASDAQ: VREX) is a leading independent designer and manufacturer of X-ray imaging components, including X-ray tubes, digital flat-panel detectors, photon-counting detectors, high-voltage connectors, and image processing software. The company operates through two primary segments: Medical (the key revenue driver supplying components for CT, diagnostic, and dental systems) and Industrial (providing linear accelerators and detectors for cargo screening and non-destructive testing). Varex operates as an upstream OEM supplier, serving major medical system integrators such as Canon Medical Systems.

Research as of 19 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Global Manufacturing Footprint Diversification (India Expansion)Expansion

Establishing low-cost manufacturing facilities in India for both detectors and tubes to mitigate geopolitical trade tariffs and improve cost efficiency.

Expected impact: Projected to contribute an additional $100 million in revenue by fiscal year 2027, focusing on radiographic products and targeting value-tier and mid-tier offerings in regions such as India, South Asia, the Middle East, and Latin America.

Sign in / Sign up to read more
InvestmentSignificant capital investment in localizing production.
TimelineDetector facility operational in 2025/2026; tube facility expected to be completed by the end of 2026 with revenue generation starting in 2027.
Photon-Counting Technology CommercializationInnovation

Developing and commercializing next-generation photon-counting detectors utilizing Cadmium Telluride (CdTe) for high-resolution medical and industrial imaging.

Expected impact: Positions Varex as a premium technology leader, driving higher-margin sales with units priced at approximately $250,000.

Sign in / Sign up to read more
InvestmentOngoing R&D allocation from the company's annual budget.
TimelineFirst customer system release anticipated in early 2027.
Debt Refinancing and Capital Structure OptimizationEfficiency

Refinancing expensive near-term debt by redeeming $368 million of 7.875% Senior Secured Notes due in 2027 with a new credit structure maturing in 2031.

Expected impact: Lowers the effective interest rate to approximately 6.15%, reducing annualized cash interest expense by $7 million to $8 million.

Sign in / Sign up to read more
InvestmentUtilized approximately $42 million of cash, including debt reduction, call premiums, and transaction fees.
TimelineCompleted in Q2 Fiscal Year 2026 (March 2026).

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Recent Acquisitions

MeVis BreastCare$1Complete
Announced 23 Sep 2023

Strengthens Varex's product offerings and market position in the mammography and breast screening segment.

Financial impact: Contributes to the stable performance of the Medical segment's mammography modality.

Sign in / Sign up to read more

Strategic Partnerships

European OEMsSupply Agreement

Varex partnered with European OEMs to supply ultra-light flat panel detectors designed to reduce total system weight by 30% and improve field mobility for security applications.

Terms: Not disclosed

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.